 Connection
Amit Tiwari to Histone Deacetylase Inhibitors
This is a "connection" page, showing publications Amit Tiwari has written about Histone Deacetylase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.550 |
|
|
|
-
Shirbhate E, Singh V, Kore R, Koch B, Veerasamy R, Tiwari AK, Rajak H. Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy. Expert Rev Anticancer Ther. 2025 Feb; 25(2):121-141.
Score: 0.231
-
Robey RW, Fitzsimmons CM, Guiblet WM, Frye WJE, Gonz?lez Dalmasy JM, Wang L, Russell DA, Huff LM, Perciaccante AJ, Ali-Rahmani F, Lipsey CC, Wade HM, Mitchell AV, Maligireddy SS, Terrero D, Butcher D, Edmondson EF, Jenkins LM, Nikitina T, Zhurkin VB, Tiwari AK, Piscopio AD, Totah RA, Bates SE, Arda HE, Gottesman MM, Batista PJ. The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors. Mol Cancer Ther. 2024 Apr 02; 23(4):464-477.
Score: 0.219
-
Shirbhate E, Singh V, Jahoriya V, Mishra A, Veerasamy R, Tiwari AK, Rajak H. Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment. Eur J Med Chem. 2024 Jan 05; 263:115938.
Score: 0.053
-
Shirbhate E, Veerasamy R, Boddu SHS, Tiwari AK, Rajak H. Histone deacetylase inhibitor-based oncolytic virotherapy: A promising strategy for cancer treatment. Drug Discov Today. 2022 06; 27(6):1689-1697.
Score: 0.047
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|